Gene Therapy for Dry AMD Using AAV to Improve Durability & Compliance

10:00 am - Tuesday 24th March 2026

  • Complement Inhibitors clinically validated for treatment of dry AMD
  • AAV vectors can potentially transform treatment from monthly injections to a single long-lasting intervention
  • Intravitreal delivery using novel AAV capsid

Speakers:

Chief Scientific Officer
Beacon Therapeutics